Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Stopping over-medication of people with intellectual disability, Autism or both (STOMP) in England part 1 – history and background of STOMP

Stopping over-medication of people with intellectual disability, Autism or both (STOMP) in... The programme – Stopping the over-medication of people with an intellectual disability, Autism or Both (STOMP) is a three-year programme supported by NHS England. Concern about the overuse of antipsychotic drugs has been a constant theme since the 1970s. However, despite a multitude of guidelines the practice continues. The report into the events at Winterbourne View not only raised concerns about the overuse of antipsychotic drugs but of antidepressants and multiple psychotropic drug use. The purpose of this paper is twofold: Part 1 is to present the history and background to the use of psychotropic drugs in intellectual disabilities, autism or both; and Part 2 presents the progress with the STOMP programme.Design/methodology/approachThe review tracks the various concerns, guidelines and attempts to tackle the issue of over medication of people with intellectual disability autism or both.FindingsThe review identifies that despite the many studies and guidelines associated with the prescribing of psychotropic drugs for people with an intellectual disability, autism or both the practice is common. Programmes that minimise the use of psychotropic drugs involve a full use of the multidisciplinary team and an availability of alternative methods of managing challenging behaviours.Originality/valueSTOMP is part of an English national agenda – Transforming care. The English Government and leading organisations across the health and care system are committed to transforming care for people with intellectual disabilities, autism or both who have a mental illness or whose behaviour challenges services. This review identifies many studies, programmes and guidelines associated with psychotropic drug use for people with an intellectual disability, autism or both. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Advances in Mental Health and Intellectual Disabilities Emerald Publishing

Stopping over-medication of people with intellectual disability, Autism or both (STOMP) in England part 1 – history and background of STOMP

Loading next page...
 
/lp/emerald-publishing/stopping-over-medication-of-people-with-intellectual-disability-autism-0xAiquI1bL
Publisher
Emerald Publishing
Copyright
© Emerald Publishing Limited
ISSN
2044-1282
DOI
10.1108/amhid-02-2018-0004
Publisher site
See Article on Publisher Site

Abstract

The programme – Stopping the over-medication of people with an intellectual disability, Autism or Both (STOMP) is a three-year programme supported by NHS England. Concern about the overuse of antipsychotic drugs has been a constant theme since the 1970s. However, despite a multitude of guidelines the practice continues. The report into the events at Winterbourne View not only raised concerns about the overuse of antipsychotic drugs but of antidepressants and multiple psychotropic drug use. The purpose of this paper is twofold: Part 1 is to present the history and background to the use of psychotropic drugs in intellectual disabilities, autism or both; and Part 2 presents the progress with the STOMP programme.Design/methodology/approachThe review tracks the various concerns, guidelines and attempts to tackle the issue of over medication of people with intellectual disability autism or both.FindingsThe review identifies that despite the many studies and guidelines associated with the prescribing of psychotropic drugs for people with an intellectual disability, autism or both the practice is common. Programmes that minimise the use of psychotropic drugs involve a full use of the multidisciplinary team and an availability of alternative methods of managing challenging behaviours.Originality/valueSTOMP is part of an English national agenda – Transforming care. The English Government and leading organisations across the health and care system are committed to transforming care for people with intellectual disabilities, autism or both who have a mental illness or whose behaviour challenges services. This review identifies many studies, programmes and guidelines associated with psychotropic drug use for people with an intellectual disability, autism or both.

Journal

Advances in Mental Health and Intellectual DisabilitiesEmerald Publishing

Published: Feb 8, 2019

Keywords: Autism; Intellectual disability; Learning disability; Polypharmacy; Call to action methodology; Psychotropic drugs

References